Project Grant R43CA306431
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $263K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Brookline, MA 02446, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
- This $1,296,385 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to accelerate the translation and commercialization of a novel, non-invasive wearable rotating magnetic field therapy device (ONCOMAGNETIC DEVICE or OMTX) targeting the treatment of brain cancers. The device generates spinning oscillating magnetic fields that have demonstrated strong, selective anti-cancer effects on patient-derived glioblastoma (GBM) cells and...
- This Project Grant award, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports a transformative research project aimed at enhancing prostate cancer (PCA) prognostication through the integration of epithelial-to-mesenchymal transition (EMT) signature markers with advanced imaging and machine learning techniques. The $399,954 award to Metastx LLC will enable analysis of PCA tissue samples to develop a novel predictive model for metastatic...
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,379,442 to Embiosys Inc. from September 2025 to August 2027 to develop and evaluate a novel wearable device that delivers induced electric field (IEF) therapy for the treatment of triple-negative breast cancer (TNBC). The key product being developed is a wearable, washable garment (camisole/tank-top) that can deliver low-intensity, intermediate frequency electromagnetic radiation...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- This federal Project Grant award, valued at $306,872 and provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to develop a new imaging system termed the Multi-Camera Array Scanner (MCAS). The MCAS will enable rapid 3D digitization and automated analysis of thick fine-needle aspiration (FNA) cytology smears, which are a critical first step in the cancer diagnosis pipeline. The project is a collaboration between Ramona Optics Inc., a small...
- This Project Grant award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) provides $647,398 to the Regents of the University of Michigan to develop quantitative bone marrow MRI biomarkers to assess the efficacy of novel molecularly targeted agents for myelofibrosis. The 5-year project aims to apply advanced MRI techniques, including Dixon imaging, diffusion-weighted imaging, and magnetization transfer imaging, to monitor bone marrow changes in...
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,995 to Omnecoil Instruments, Inc. to conduct feasibility testing of a novel system for integrated endorectal MRI and in-bore biopsy of the prostate. The goal is to develop a faster, more efficient, and more accurate diagnostic test for the estimated 1.4 million men who develop prostate cancer each year. The study will recruit 30 men...
- The federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research Program (CFDA 93.394) provided $1,164,814 to O2M Technologies LLC to develop an advanced imaging system using pulse electron paramagnetic resonance (PEPR) techniques. The goal is to create a fast and precise method for measuring partial oxygen pressure (pO2) in tissues, which can guide cancer treatment and other medical applications. The project involves establishing the hardware for...